Artelo Biosciences Achieves First Patient Dosing in Phase 2 DREAM Study for Glaucoma

A peripherally selective synthetic cannabinoid API is now in Phase 2 ophthalmology testing, raising immediate CMC and regulatory questions for development teams tracking novel cannabinoid-derived compounds. Artelo Biosciences confirmed on 10 August 2026 that the first patient has been dosed in the DREAM study (Determining the Role of synthetic cannabinoids in Eye pressure And tolerability Measurements), an investigator-led trial evaluating ART27.13 for intraocular pressure reduction in glaucoma and ocular hypertension.

The study is sponsored by the Belfast Health and Social Care Trust and conducted through the Northern Ireland Clinical Trials Unit, with funding provided by Glaucoma UK and the HSC R&D Division. Principal investigator Professor Augusto Azuara-Blanco, Clinical Professor of Ophthalmology at Queen's University Belfast, is leading the trial. Initial results are anticipated in Q4 2026.

ART27.13 is a benzimidazole derivative and dual CB1/CB2 agonist originally developed by AstraZeneca. Its peripherally selective profile is central to the DREAM study rationale: prior oral and topical cannabinoid programmes in glaucoma have been limited by CNS-mediated adverse effects, and ART27.13's design targets ocular and peripheral receptors while minimising central nervous system exposure. The compound has accumulated data across seven prior clinical studies involving more than 280 participants, providing a safety dataset that supports the Phase 2 dose selection.

For regulatory affairs and CMC teams, synthetic cannabinoid APIs occupy a nuanced position. Depending on jurisdiction, scheduling status can affect import, handling, and labelling requirements under frameworks analogous to 21 CFR Part 211 in the US and equivalent EU GMP annexes. The oral, once-daily formulation also introduces standard solid-dosage process validation obligations, though the ophthalmic indication does not add sterility assurance requirements here given the systemic route of administration.

Glaucoma affects more than 80 million people globally, and elevated IOP remains the primary modifiable risk factor for disease progression. Current standard-of-care topical therapies face documented adherence and local tolerability limitations, creating a clinical gap that an orally administered agent could address if efficacy and tolerability data from DREAM prove supportive.

Artelo is concurrently running the CAReS Phase 2 study evaluating ART27.13 in cancer-related anorexia and weight loss, meaning the compound's regulatory dossier is accumulating data across two distinct indications simultaneously.

The Q4 2026 interim readout from DREAM will be the first controlled evidence of whether peripheral CB1/CB2 agonism produces a clinically meaningful IOP reduction via the oral route.

Source: Artelo Biosciences, Inc. via GlobeNewswire, 10 August 2026.